CoChat

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study

Open access

The DOI matches its Crossref record; 57 of the 60 references it cites were found in a registry or an index; 9 of the 24 sources its claims cite were checked for support.

Abstract

Background Models of Alzheimer's disease propose a sequence of amyloid β (Aβ) accumulation, hypometabolism, and structural decline that precedes the onset of clinical dementia. These pathological features evolve both temporally and spatially in the brain. In this study, we aimed to characterise where in the brain and when in the course of the disease neuroimaging biomarkers become abnormal.Methods Between Jan 1, 2009, and Dec 31, 2015, we analysed data from mutation non-carriers, asymptomatic carriers, and symptomatic carriers from families carrying gene mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein (APP) enrolled in the Dominantly Inherited Alzheimer's Network. We analysed 11 C-Pittsburgh Compound B (11 C-PiB) PET, 18 F-Fluorodeoxyglucose (18 F-FDG) PET, and structural MRI data using regions of interest to assess change throughout the brain. We estimated rates of biomarker change as a function of estimated years to symptom onset at baseline using linear mixed-effects models and determined the earliest point at which biomarker trajectories differed between mutation carriers and non-carriers. This study is registered at ClinicalTrials.gov (number NCT00869817) FINDINGS: 11 C-PiB PET was available for 346 individuals (162 with longitudinal imaging), 18 F-FDG PET was available for 352 individuals (175 with longitudinal imaging), and MRI data were available for 377 individuals (201 with longitudinal imaging). We found a sequence to pathological changes, with rates of Aβ deposition in mutation carriers being significantly different from those in non-carriers first (across regions that showed a significant difference, at a mean of 18·9 years [SD 3·3] before expected onset), followed by hypometabolism (14·1 years [5·1] before expected onset), and lastly structural decline (4·7 years [4·2] before expected onset). This biomarker ordering was preserved in most, but not all, regions. The temporal emergence within a biomarker varied across the brain, with the precuneus being the first cortical region for each method to show divergence between groups (22·2 years before expected onset for Aβ accumulation, 18·8 years before expected onset for hypometabolism, and 13·0 years before expected onset for cortical thinning).Interpretation Mutation carriers had elevations in Aβ deposition, reduced glucose metabolism, and cortical thinning compared with non-carriers which preceded the expected onset of dementia. Accrual of these pathologies varied throughout the brain, suggesting differential regional and temporal vulnerabilities to Aβ, metabolic decline, and structural atrophy, which should be taken into account when using biomarkers in a clinical setting as well as designing and evaluating clinical trials.Funding US National Institutes of Health, the German Center for Neurodegenerative Diseases, and the Medical Research Council Dementias Platform UK.

Overview

CoChat Summary

TL;DR

In the DIAN longitudinal cohort, mutation carriers showed earlier and regionally variable neuroimaging biomarker changes than non-carriers, with Aβ deposition diverging first, followed by hypometabolism and then structural decline. The precuneus was the earliest cortical region to show divergence across all three modalities.

Key findings

  • Among regions with significant group differences, rates of Aβ deposition in mutation carriers diverged first at an average estimated years from symptom onset (EYO) of −18·9 (SD 3·3), followed by hypometabolism at −14·1 (SD 5·1) and structural decline at −4·7 (SD 4·2).
  • The precuneus was the first cortical region in each modality: Aβ accumulation diverged at EYO −22·2, hypometabolism at −18·8, and cortical thinning at −13·0.
  • PiB PET showed significantly greater longitudinal Aβ accumulation in 32/34 cortical regions in mutation carriers versus non-carriers, with divergence from EYO −22·2 to −2·5; all but the cuneus (−2·5) occurred before EYO −15. FDG PET showed significant hypometabolism in 8/34 cortical regions (EYO −18·8 to −2·8) and no subcortical regions. MRI showed increased atrophy in 24/34 cortical and 4/7 subcortical regions (EYO −13·0 to 2·3).
  • Regional relationships were heterogeneous: all regions with metabolic decreases had abnormal Aβ accumulation, but many regions with abnormal Aβ accumulation did not show elevated metabolic decline; some regions, such as the hippocampus, had structural declines without Aβ or FDG changes.

Methods

  • Participants were from families with PSEN1, PSEN2, or APP mutations in the Dominantly Inherited Alzheimer Network observational study, recruited from 14 sites in the United States, Great Britain, Germany, and Australia between January 1, 2009, and December 31, 2015; Dutch and Flemish APP mutation families were excluded. Analyses included 346 individuals with PiB PET (162 longitudinal), 352 with FDG PET (175 longitudinal), and 377 with MRI (201 longitudinal); longitudinal subjects averaged 2·4 visits (SD 0·8) and 2·7 years (SD 1·1) of data.
  • Imaging used [11C]Pittsburgh Compound B PET, [18F]fluorodeoxyglucose PET, and structural MRI with ADNI protocol; PET data were converted to SUVRs relative to cerebellar grey matter and partial volume corrected, and MRI was processed with FreeSurfer to define 34 cortical and 7 subcortical regions of interest.
  • Bayesian multivariate linear mixed-effects models were fit in Stan, separately for cortical and subcortical regions for each modality (six models total), with fixed effects for mutation status, time from baseline, baseline EYO, and interactions; significance was based on 99% equal-tailed credible intervals not overlapping zero.

Limitations

  • Stated in the paper: most longitudinal subjects had limited follow-up (average 2·4 visits), results at the edges of the EYO range may be disproportionately influenced by outliers, and there were only modest numbers of subjects with PSEN2 and APP mutations.
  • Stated in the paper: no individual has data across the entire disease window, results represent population rather than individual subject effects, some individuals differ from population trajectories, and imaging data alone may not be sufficient for individual-level disease staging.
  • Stated in the paper: the temporal ordering is relative rather than absolute and depends on the EYO definition; PET/MRI findings are constrained by technique sensitivity and signal-to-noise; partial volume correction and cerebellum reference region choices may affect trajectories; and ADAD as a model for sporadic AD requires direct comparisons. Evident from the text: the study did not include tau or inflammation biomarkers, which the authors note may help explain heterogeneous regional relationships.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(18)30028-0

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Modeling longitudinal change in the precuneus for PiB (top), FDG (middle), and cortical thickness (bottom). The left-hand panels (A, D, & G) depict the model estimates of longitudinal biomarkers. The middle panels (B, E, & H) depict the estimated rate of change across the course of the disease for mutation carriers and non-carriers. Individual random effect slope estimates are plotted as colored dots. The right hand panels (C, F, and I) depict the difference in rate of biomarker change between mutation carriers and non-carriers across the course of the disease. For both the middle and right-hand panels the shaded areas represent 99% credible intervals around the model estimates. The credible intervals are drawn from the actual distributions of model fits derived by the Hamilton Markov Chain Monte Carlos analyses. Any point in this difference curves where the shaded area is not touching the zero axis is a point in the disease progression (as measured by EYO) where the biomarker accumulation rate is different between groups. The first EYO point that was significantly different between groups was considered the initial diverge between groups. Figures depicting the model results for every ROI are available in supplemental materials. To avoid inadvertently revealing mutation status figures are displayed with baseline EYO −29 to +10.
Figure 1 Modeling longitudinal change in the precuneus for PiB (top), FDG (middle), and cortical thickness (bottom). The left-hand panels (A, D, & G) depict the model estimates of longitudinal biomarkers. The middle panels (B, E, & H) depict the estimated rate of change across the course of the disease for mutation carriers and non-carriers. Individual random effect slope estimates are plotted as colored dots. The right hand panels (C, F, and I) depict the difference in rate of biomarker change between mutation carriers and non-carriers across the course of the disease. For both the middle and right-hand panels the shaded areas represent 99% credible intervals around the model estimates. The credible intervals are drawn from the actual distributions of model fits derived by the Hamilton Markov Chain Monte Carlos analyses. Any point in this difference curves where the shaded area is not touching the zero axis is a point in the disease progression (as measured by EYO) where the biomarker accumulation rate is different between groups. The first EYO point that was significantly different between groups was considered the initial diverge between groups. Figures depicting the model results for every ROI are available in supplemental materials. To avoid inadvertently revealing mutation status figures are displayed with baseline EYO −29 to +10.CC BY-NC-ND · PubMed Central
Figure 2 Emergence of neuroimaging biomarkers. The color scale represents the first point in the disease relative to estimated age at onset (EYO) where rates of biomarker change in that cortical region are significantly different between mutation carriers and non-carriers (akin to the first point where credible interval are different from zero in Figure 1 right panels). There is a temporal evolution where increased Aβ deposition precedes hypometabolism that in turn is followed by cortical thinning. Information for all modalities and regions is presented in numeric form in Supplemental Tables 1 and 2.
Figure 2 Emergence of neuroimaging biomarkers. The color scale represents the first point in the disease relative to estimated age at onset (EYO) where rates of biomarker change in that cortical region are significantly different between mutation carriers and non-carriers (akin to the first point where credible interval are different from zero in Figure 1 right panels). There is a temporal evolution where increased Aβ deposition precedes hypometabolism that in turn is followed by cortical thinning. Information for all modalities and regions is presented in numeric form in Supplemental Tables 1 and 2.CC BY-NC-ND · PubMed Central
Figure 3 Trajectories of biomarker accumulation in mutation carriers for three cortical (top) and three subcortical regions (bottom) for PiB (left), FDG (middle), and structural MRI (right) that highlight different patterns of change seen in different brain regions.
Figure 3 Trajectories of biomarker accumulation in mutation carriers for three cortical (top) and three subcortical regions (bottom) for PiB (left), FDG (middle), and structural MRI (right) that highlight different patterns of change seen in different brain regions.CC BY-NC-ND · PubMed Central
Figure 4 Depictions of model estimates of rate of change in PiB (top), FDG (middle), and cortical thickness (bottom) in mutation carriers at an EYO of −25, −15, −5, and +5.
Figure 4 Depictions of model estimates of rate of change in PiB (top), FDG (middle), and cortical thickness (bottom) in mutation carriers at an EYO of −25, −15, −5, and +5.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

5 Valid · 0 Not valid · 4 Not checked · 74 Own results and interpretations

44 more claims

Create a free account to see all 83 claims and to verify the 15 references still open.

See all claims — free account
  • Probably not a substantial claim. 16
  • It may state two separate claims as one. 23

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

12 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 57 references

Cited by

See all 615

Metadata

Authors
Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., Cairns, N. J., Hassenstab, J., Marcus, D. S., Fagan, A. M., Jack, C. R., Hornbeck, R. C., Paumier, K. L., Ances, B. M., Berman, S. B., Brickman, A. M., Cash, D. M., Chhatwal, J. P., Correia, S., Förster, S., Fox, N. C., Graff-Radford, N. R., la Fougère, C., Levin, J., Masters, C. L., Rossor, M. N., Salloway, S., Saykin, A. J., Schofield, P. R., Thompson, P. M., Weiner, M. M., Holtzman, D. M., Raichle, M. E., Morris, J. C., Bateman, R. J., & Benzinger, T. L. S.
Affiliations
  • Washington University in St. Louis (US)
  • Mayo Clinic (US)
  • University of Pittsburgh (US)
  • Columbia University (US)
  • UCL Queen Square Institute of Neurology (GB)
  • Harvard University (US)
  • Brown University (US)
  • German Center for Neurodegenerative Diseases (DE)
  • The University of Melbourne (AU)
  • UNSW Sydney (AU)
  • University of Southern California (US)
Corresponding author
Gordon, Brian A
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2018-03
Volume
17
Issue
3
Pages
241-250
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2787666045
Cited by
602
References
60
Citations by year
2026: 46 · 2025: 68 · 2024: 89 · 2023: 82 · 2022: 80 · 2021: 109 · 2020: 59 · 2019: 42 · 2018: 25
FWCI
45.91
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
  • UCL Discovery (University College London) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
  • DZNE Pub (submittedVersion)
Funders
  • U.S. Department of Defense
  • Alzheimer's Association
  • Larry L. Hillblom Foundation
  • Alzheimer's Drug Discovery Foundation
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline (P01AG026276)
  • Sanofi
  • Biogen
  • Patient-Centered Outcomes Research Institute
  • Synarc
  • Foundation for Barnes-Jewish Hospital
  • BioClinica
  • Judith Jane Mason and Harold Stannett Williams Memorial Foundation
  • Hope Center for Neurological Disorders
  • Alzheimer's Society
  • National Institute for Health and Care Research
  • Rosetrees Trust (M668-CD1)
  • Eisai
  • Deutsches Zentrum für Neurodegenerative Erkrankungen
  • Servier
  • H. Lundbeck A/S
  • Grifols
  • Dementias Platform UK
  • National Institutes of Health (1s10rr022984-01a1, UL1TR000448, 1s10od018091-01, UF01AG032438, UL1TR002345)
  • Genentech
  • Novartis Pharma
  • Avid Radiopharmaceuticals
  • Medical Research Council (MR/L023784/2, MR/L023784/1)
  • National Health and Medical Research Council
  • National Institute on Aging (K23AG049087, UF1AG032438, P50AG005681, P01AG003991, U19AG032438, U01AG032438, P01AG026276, K01AG053474)
  • National Institute of Mental Health
  • National Institute of Neurological Disorders and Stroke (P01NS080675, P30NS048056, P30NS098577)
  • National Institute of Biomedical Imaging and Bioengineering (P41EB015922, R01EB009352)
  • National Center for Research Resources (S10 RR022984)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
autosomal dominant Alzheimer's disease, neuroimaging biomarkers, amyloid-beta deposition, hypometabolism, presenilin 1, presenilin 2, amyloid precursor protein, 11C-PiB PET, 18F-FDG PET, structural MRI, mutation carriers, asymptomatic carriers, precuneus, brain atrophy, disease progression
MeSH terms
Adult, Alzheimer Disease, Aniline Compounds, Brain, Brain Mapping, Family Health, Female, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Thiazoles, Amyloid beta-Protein Precursor, Statistics, Nonparametric, Fluorodeoxyglucose F18, Positron-Emission Tomography, Presenilin-1, Presenilin-2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. https://app.cochat.ai/papers/10.1016/s1474-4422(18)30028-0
The paper
Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., Cairns, N. J., Hassenstab, J., Marcus, D. S., Fagan, A. M., Jack, C. R., Hornbeck, R. C., Paumier, K. L., Ances, B. M., Berman, S. B., . . . Benzinger, T. L. S. (2018). Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(18)30028-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.